Sulfagenix holds the key unlocking the regenerating abilities of the body. Sulfagenix, Inc. is built on decades of research on modifying existing molecules to improve safety, bioavailability and efficacy for new uses. SG1002 (sodium polysulthionate), Sulfagenix’s clinical-stage prodrug, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease.